AUPHAurinia Pharmaceuticals Inc.
$16.65+28% 1Y
$16.65
$11.0552 weeks$18.62
AUPH in its own filings
Nothing in AUPH's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
325
Events found in the filings · across 613 filings · the record starts in 2014
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 19, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 26, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026On August 19, 2026, Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, “Aurinia”) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (“Teva”) to resolve patent infringement litigation …Other event · Form 8-K
- Aug 6, 2026Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.Earnings release · press release
- May 11, 2026As previously disclosed by Aurinia Pharmaceuticals Inc. (“Ultimate Parent” or “Aurinia”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the …Acquisition or disposition completed · Form 8-K
- May 7, 2026Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.Earnings release · press release
- Apr 3, 2026Agreement and Plan of Merger On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Kezar Life Sciences, Inc., a Delaware corporation (the “Company” or “Kezar”), Parent, Aurinia Merger Sub, Inc., a Delaware …Material agreement entered · Form 8-K
- Mar 23, 2026Appointment of Officers Effective March 23, 2026, the Board of Directors of Aurinia Pharmaceuticals Inc. (“Aurinia”) appointed Kevin Tang as Aurinia’s Chief Executive Officer and as Aurinia’s principal executive officer.Director or officer change · Form 8-K
- Feb 26, 2026Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…